Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease)

Principal Inclusion Criteria: Patients diagnosed GO with CAS ≥ 4 and an index of severity, according EUGOGO guidelines, 1. moderately to severely or 2. sight-threatening GO, after receiving corticosteroid pulse treatment due to: * Poor response to intravenous corticosteroid pulses Or * Recurrence of the GO, after treatment with intravenous corticosteroids Exclusion Criteria: * Orbital decompression surgery needed immediately * Active smoker * Patients who could need treatment with radioactive iodine or thyroidectomy during the study * Pregnant patient or patient who is planning to become pregnant during the study * History of chronic recurrent or active infection * History of intestinal ulceration or diverticulitis * Patients with a history of chronic liver disease or liver disorders: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) above 5 times upper limit of normal (ULN) * History of HIV, hepatitis C or hepatitis B Positive * Neutrophil count \< 0.5 × 109/L or a platelet count \< 50×103/μL * Simultaneous use or contraindications to the use of immunosuppressive agents * A treatment with another investigational drug within four weeks of selection or five half-lives of study drug * Cardiovascular or cerebrovascular disease clinically significant * Uncontrolled diabetes mellitus * Use of corticosteroids during four weeks before to inclusion period * History of reactions or anaphylactic allergic severe human monoclonal antibodies, humanized or murine * Uncontrolled pathologies, whose exacerbations are treated with corticosteroids